Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
B. Ghanim, M. A. Hoda, A. Scheed, M. Winter, A. Alimohammadi, C. Aigener, S. Thagavi, G. Lang, A. Mohamed, B. Hegedus, W. Berger, W. Klepetko (Vienna, Austria). The impact of multimodal treatment approaches in patients with malignant pleural mesothelioma. Eur Respir J 2010; 36: Suppl. 54, 455

Member's Comments

No comment yet.

Related content which might interest you: Videothoracoscopy in diagnosis and palliative treatment of malignant pleural mesothelioma Source: Annual Congress 2008 - Biology and diagnosis of thoracic tumours Year: 2008 Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma? Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003 Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005 Multimodality therapy for malignant pleural mesothelioma Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004 ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma Source: Guideline 2020 Year: 2020 ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma Source: Eur Respir J, 55 (6) 1900953; 10.1183/13993003.00953-2019 Year: 2020 Bevacizumab-targeted therapy for malignant pleural mesothelioma Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs Year: 2017 Evaluation of response to chemotherapy for malignant pleural mesothelioma and suggestion of a new method Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002 Multimodal therapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002 Prognostic value of treatment outcomes patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Three dimensional evaluation of chemotherapy response in malign pleural mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 754s Year: 2007 Chemotherapy for treatment of malignant pleural mesothelioma Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004 Malignant pleural mesothelioma: our multimodality approach Source: Eur Respir J 2002; 20: Suppl. 38, 40s Year: 2002 Are patients with malignant pleural effusions being referred appropriately for surgical intervention? Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008 Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018 Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients Source: Eur Respir J 2011; 38: 1425-1430 Year: 2011 In patients with treatment-sensitive cancers, does systemic anti-cancer therapy increase the chance of malignant pleural effusion control? Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020 Multimodal management of malignant pleural mesothelioma: where are we today? Source: Eur Respir J 2014; 44: 754-764 Year: 2014 Videothoracoscopy in the treatment of malignant pleural effusions Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009 Is prophylactic radiotherapy at intervention site always neccessary in malign pleural mesothelioma? Source: Eur Respir J 2006; 28: Suppl. 50, 751s Year: 2006